Prime Medicine (PRME) director receives 75,000 stock options at $3.06

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, with all 75,000 options shown as held after this grant.

The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, as long as Chung continues to provide service to the company through that vesting date. The options expire on June 5, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chung Wendy

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 75,000 options Exercise price: $3.06 per share Post-grant derivative holdings: 75,000 derivative securities +2 more

5 metrics

Options granted 75,000 options Stock Option (right to buy) grant to director

Exercise price $3.06 per share Conversion or exercise price for the options

Post-grant derivative holdings 75,000 derivative securities Total options held after this transaction

Vesting date Earlier of June 5, 2027 or next annual meeting Full vesting condition subject to continuous service

Expiration date June 5, 2036 Option expiration if not exercised

Key Terms

Stock Option (right to buy), derivative securities, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

derivative securities financial

"derivativeTransactionCount: 1 derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

exercise price financial

"conversion_or_exercise_price: 3.0600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to this option shall vest in full upon the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chung Wendy

(Last)

(First)

(Middle)

C/O PRIME MEDICINE, INC.

60 FIRST STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.06	06/05/2026		A		75,000		⁽¹⁾	06/05/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

	/s/ Ryan Brown, attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Prime Medicine (PRME) director Wendy Chung report in this Form 4?

Wendy Chung reported a grant of stock options covering 75,000 shares of Prime Medicine common stock. These options were awarded at a $3.06 exercise price and represent a compensation-related acquisition, not an open-market stock purchase or sale.

How many Prime Medicine (PRME) options were granted to Wendy Chung?

Wendy Chung was granted stock options on 75,000 underlying shares of Prime Medicine common stock. The Form 4 shows 75,000 derivative securities held after the transaction, all tied to this single award reported on the filing date.

What is the exercise price of Wendy Chung’s Prime Medicine (PRME) stock options?

The stock options granted to Wendy Chung carry an exercise price of $3.06 per share. This means she can buy Prime Medicine common stock at $3.06 when the options are vested and exercised, subject to the option terms and expiration date.

When do Wendy Chung’s Prime Medicine (PRME) options vest?

The options vest in full on the earlier of June 5, 2027, or the date of Prime Medicine’s next annual meeting of stockholders. Vesting is conditional on her continuous service to the company through the applicable vesting date, as disclosed.

What is the expiration date of the Prime Medicine (PRME) options granted to Wendy Chung?

The stock options granted to Wendy Chung expire on June 5, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur between vesting and that 2036 expiration under the award’s terms.

Is Wendy Chung’s Form 4 transaction a stock purchase or sale of Prime Medicine (PRME)?

The Form 4 reports a grant of derivative securities, not an open-market stock purchase or sale. The transaction code A reflects a grant or award acquisition of stock options, which may lead to future share purchases upon exercise at $3.06.